NCT00328939 is a Phase 3 clinical trial of ARIXTRA infusion in Thromboembolism, sponsored by GlaxoSmithKline.

Who is sponsoring NCT00328939?

NCT00328939 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT00328939?

Interventions in NCT00328939: ARIXTRA infusion, Enoxaparine infusion.

What condition does NCT00328939 study?

NCT00328939 studies Thromboembolism, Knee Replacement, Hip Replacement.

Is NCT00328939 still recruiting?

NCT00328939 is currently completed. Last updated 31 May 2012.

Last reviewed 2012-05-31 · How we verify

NCT00328939

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Randomized, Single Blind, Parallel Study to Compare the Safety and Efficacy of ARIXTRA to Enoxaparine in Patients Undergoing Elective Major Hip or Knee Replacement or a Revision of Components.

Completed Phase 3 Last updated 31 May 2012

What this trial tests

Phase 3 trial testing ARIXTRA infusion in Thromboembolism in 240 participants. Completed.

Timeline

1 May 2004

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	240
Start date	1 May 2004
Sites	7 locations across China

Drugs / interventions tested

ARIXTRA infusion — full drug profile →
Enoxaparine infusion — full drug profile →

Conditions studied

Thromboembolism — all drugs for Thromboembolism →
Knee Replacement — all drugs for Knee Replacement →
Hip Replacement — all drugs for Hip Replacement →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

Adults 18 to 75, any sex, with Thromboembolism or Knee Replacement. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Occurrence of overall DVT (deep vein thrombosis) events confirmed by ultrasound result within day 5-11 post operation.

Sponsor's own description

This is a local registration study in China to compare the safety and efficacy of ARIXTRA to Enoxaparine in patients undergoing elective major hip or knee replacement or a revision of components.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Thromboembolism

Currently open trials in the same condition.

NCT06657924 — Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery · Phase 2 · recruiting
NCT06442267 — Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support · Phase 4 · recruiting
NCT06443905 — Xueshuantong Injection (Lyophilized) in the Prevention of Venous Thromboembolism (VTE) in Hospitalized Patients · active not recruiting
NCT05301348 — In Vivo Detection of Circulating Clots in Patients With Thromboembolism · NA · recruiting
NCT06627933 — Optimization of Management in Patients With Cardiovascular Disease After Lower Limb Joint Replacement · recruiting

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00328939 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 31 May 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00328939.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing